A number of other analysts have also commented on GUD. Raymond James set a C$10.25 target price on shares of Knight Therapeutics and gave the stock an outperform rating in a report on Thursday, July 12th. TD Securities lifted their target price on shares of Knight Therapeutics from C$9.50 to C$10.00 in a report on Friday, August 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock has a consensus rating of Buy and an average target price of C$10.15.
GUD traded up C$0.11 during trading on Friday, reaching C$8.30. 198,100 shares of the company’s stock were exchanged, compared to its average volume of 134,380. Knight Therapeutics has a fifty-two week low of C$7.38 and a fifty-two week high of C$8.81.
Knight Therapeutics Company Profile
Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.
Further Reading: The Discount Rate – What You Need to Know
Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.